Immunosuppressive agents in organ transplantation

Hospital Medicine

Volumn 60, Issue 5, 1999, Pages 364-369

  Magee, Colm C ^a   Denton, Mark D ^a   Milford, Edgar L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

DRUG ANTAGONISM; GRAFT REJECTION; HUMAN; ORGAN TRANSPLANTATION; REVIEW;

CALCINEURIN; CYCLOSPORINS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS;

EID: 0033127365     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.1999.60.5.1118     Document Type: Article

References (22)

1. Burke JJ. Pirsch JD, Ramos EL et al (1994) Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331 : 358-63
2. Cecka JM (1997) The UNOS Scientific Renal Transplant Registry -Ten years of kidney transplants. In: Cecka JM, Terasaki E, eds. Clinical Transplants 1997. UCLA Tissue Typing Laboratory, Los Angeles
3. Gruessner RW, Burke GW, Stratta R et al (1996) A multicenter analysis of the first experience with FK.506 for induction and rescue therapy after pancreas transplantation. Transplantation 61: 261-73
4. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63: 39
5. Kahan BD, Welsh M, Schoenberg L et al ( 1996) Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62:599-606
6. Katznelson S, Cecka JM (1997) Immunosuppressive regimens and their effects on renal allograft outcome. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1996. UCLA Tissue Typing Laboratory, Los Angelos: 361-71
7. Kirk AD, Harlan DM, Armstrong NN et al (1997) CTLA4-fg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc NatlAcadSci USA 94: 8789-94
8. Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66: 507-15
9. MacGregor MS, Bradley JA (1995) Overview of immunosuppressive therapy in organ transplantation. Br J Hasp Med 54: 276-84
10. Mathew TH (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65: 1450-4
11. Mayer AD, Dmitrewski J, Squifflet JP et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64: 436
12. Mycophenolate Mofetil Renal Refractory Rejection Study Group (1996) Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation 61: 722-9
13. Nashan B, Moore R, Amlot P, Schmidt AG. Abeywickrama K, Soulillou JP (1997) Randomised trial of basiliximab vs placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group, ion350: 1193-8
14. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977-83
15. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ (1996) Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 348: 643-8
16. Roth D, Colona J, Burke GW, Ciancio G. Esquenazi V, Miller J (1998) Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 65: 248-52
17. Sayegh MH, Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 33: 1813-21
18. Shah MB, Martin JE, SchroederTJ, First MR (1998) Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis. Transplant Proc 30: 1697-700
19. Sinclair NR (1992) Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with wellfunctioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 147: 645-57
20. Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338: 161 -5
21. Woodle ES, Thistlethwaite JR. Gordon JH, et al (1996) A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 62: 594-9
22. Woolfson RG, Neild GH (1997) Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 12:2054-6